Skip to content

Pre-implantation Genetic Testing for Aneuploidies (PGT-A)

Screening embryos for chromosomal abnormalities before transfer to improve IVF treatment success.

Helpful tools

What is Pre-implantation Genetic Testing for Aneuploidies (PGT-A)?

At Sunfert, we offer Pre-implantation Genetic Testing for Aneuploidies (PGT-A) as a genetic screening tool to examine embryos created through IVF before they are transferred to the uterus.

PGT-A helps us identify whether an embryo has the correct number of chromosomes. Chromosomes carry genetic information, and a healthy embryo typically contains 46 chromosomes arranged in 23 pairs.

How are Embryos Screened using Advanced Genetic Technology?

To perform PGT-A accurately, we use a technology called Next-Generation Sequencing (NGS) at Sunfert. This is a top-notch advanced genetic testing technology in the industry that allows us to examine the DNA of an embryo in detail, helping us determine whether it has the correct number of chromosomes.

During the PGT-A process, a few cells are carefully taken from the embryo and analysed using NGS. This technology can screen all 23 pairs of chromosomes at once with high precision, allowing us to identify embryos that are chromosomally normal as well as those with chromosomal abnormalities. By selecting embryos with the correct chromosomal count, PGT-A helps improve the chances of successful implantation, supports a healthier pregnancy, and reduces the risk of miscarriage for patients undergoing IVF.

What are Chromosomal Abnormalities?

A normal embryo has 23 pairs of chromosomes. Chromosomal abnormalities occur when there is an extra chromosome, a missing chromosome, or a structural imbalance in the embryo. These abnormalities may increase the risk of:

  • Implantation failure
  • Miscarriage
  • Genetic disorders

By screening embryos before transfer, we aim to select embryos with the correct chromosomal count to improve the chance of establishing a healthy pregnancy.

Examples of Chromosomal Abnormalities

Some disorders that arise from chromosomal abnormalities include:

  • Down’s Syndrome (Trisomy 21): caused by extra copy of chromosome 21
  • Edwards’ Syndrome (Trisomy 18): caused by extra copy of chromosome 18
  • Patau’s Syndrome (Trisomy 13): caused by extra copy of chromosome 13
  • Turner Syndrome (Monosomy X): caused by a missing copy of chromosome X in female embryos
  • Other numerical chromosomal abnormalities (aneuploidies) may lead to implantation failure or miscarriage

When combining IVF treatment with PGT-A, we can reduce the risk of transferring embryos with detectable chromosomal abnormalities.

Who Should Consider PGT-A?

We generally recommend PGT-A for individuals or couples who:

  • are at an advanced maternal age
  • have had recurrent miscarriages
  • have experienced recurrent implantation failure
  • have previously had a pregnancy affected by chromosomal abnormalities
  • produce multiple embryos and want to prioritise chromosomally normal embryos
  • wish to reduce the risk of transferring embryos affected by disorders such as Down’s Syndrome

At Sunfert, we assess each case individually to determine whether PGT-A is clinically appropriate for our patients’ fertility journey.

Our data and research at Sunfert shows that PGT-A benefits women of all age groups, especially those with advanced maternal age. As age increases, the number of transferable embryos decreases, and PGT-A can help identify the healthiest embryos for a higher chance of success.

The chart below is based on data from 4,497 blastocysts biopsied at Sunfert Group. The findings show that transferable embryo rates were highest among women below 35 years old, reaching up to 80%, while the transferable embryo rate among women aged 42 years old and above was approximately 10%.

Chart showing transferable embryo rates by maternal age based on data from 4,497 blastocysts biopsied at Sunfert International Fertility Centre in Malaysia.

Who Can Benefit from PGT-A?

PGT-A can benefit patients who want greater confidence in embryo selection before transfer.

We often see positive value for those who:

  • are planning pregnancy at a later reproductive age
  • want to minimise miscarriage risk linked to chromosomal abnormalities
  • aim to increase the IVF treatment success rate with a more targeted, evidence-based embryo transfer plan.

For many patients, it provides reassurance by giving us additional genetic insight into the quality of their embryos.

Does PGT-A Improve IVF Success Rates?

Based on data collected from our patients, incorporating Pre-Implantation Genetic Testing (PGT) into IVF treatment improved IVF success rates and outcomes, including higher clinical pregnancy rates and implantation rates.

The comparison below shows the differences in clinical pregnancy and implantation rates between patients who underwent IVF with PGT and those who underwent IVF without PGT.

Sunfert Clinical Pregnancy Rate

Age GroupNon PGTPGT
<3562.3%59.7%
35 - 3753.5%71.7%
38 - 4046.3%67.1%
>41 - 4217.4%48.2%
Overall54.8%64.5%

 

Sunfert Clinical Implantation Rate

Age GroupNon PGTPGT
<3557.9%60.0%
35 - 3747.7%69.9%
38 - 4043.3%66.3%
>41 - 4211.1%48.2%
Overall49.5%63.9%

 

Notes:

  • The Sunfert Clinical Pregnancy Rate and Implantation Rate (success rate) shown above were calculated based on data collected at Sunfert Bangsar South in 2024.
  • In patients below 35, PGT is less frequently indicated. As a result, outcomes in this group are based on a smaller sample size, which may affect the observed clinical pregnancy rate.

Click here to learn more about Sunfert IVF Success Rate.

How is PGT-A Performed at Sunfert?

Step 1: IVF Treatment & Embryo Development

We stimulate the ovaries, retrieve the eggs, and fertilise them in our laboratory through IVF/ICSI.
The embryos are cultured until they reach the blastocyst stage (Day 5 or Day 6).

 

Step 2: Embryo Biopsy

Performed by our highly-trained embryologists or genetic scientists, a tiny cluster of cells is collected from the outer layer of the blastocyst (trophectoderm biopsy).

 

Step 3: Pre-implantation Genetic Testing for Aneuploidies

The biopsied cells undergo chromosomal testing using advanced genetic technology to determine if the embryo has the correct number of chromosomes.

The results are generated and shared with our patients and fertility specialists within 2 to 3 weeks.

 

Step 4: Embryo Selection and Transfer

Embryos identified as chromosomally normal (euploid) are prioritised for transfer in a subsequent cycle to improve the likelihood of a healthy pregnancy. 

Mosaic embryos, which contain a mix of normal and abnormal cells, may be considered for transfer in selected cases following careful clinical evaluation and counselling.

Take the Next Step with Our Fertility Specialists

If you are facing fertility challenges, start with a consultation at Sunfert. We will guide you through your fertility journey with expertise and compassionate care. 

Make an appointment with our Fertility Specialist today and take the next step toward your parenthood goals.

What is Pre-implantation Genetic Testing for Aneuploidies (PGT-A)?

Pre-implantation Genetic Testing for Aneuploidies (PGT-A) is an advanced genetic screening technique used during IVF to assess whether embryos have the correct number of chromosomes before transfer.

A healthy embryo typically contains 46 chromosomes (23 pairs). By identifying chromosomally normal (euploid) embryos, PGT-A helps improve implantation rates and supports a healthier pregnancy outcome.

What is the main purpose of PGT-A in IVF treatment?

The primary purpose of PGT-A is to select embryos with the correct chromosomal number, which can:

  • improve chances of successful implantation
  • reduce the risk of miscarriage
  • lower the likelihood of chromosomal disorders 

This allows fertility specialists to make more informed, evidence-based decisions during embryo transfer.

What are common examples of chromosomal abnormalities detected by PGT-A?

Common chromosomal conditions include:

  • Down’s Syndrome (Trisomy 21)
  • Edwards’ Syndrome (Trisomy 18)
  • Patau’s Syndrome (Trisomy 13)
  • Turner Syndrome (Monosomy X) 

PGT-A can detect these numerical abnormalities before embryo transfer, helping reduce associated risks.

What are the advantages of combining IVF with PGT-A?

Combining IVF with PGT-A offers several advantages: 

  • more precise embryo selection
  • reduced risk of chromosomal abnormalities
  • improved confidence during transfer decisions
  • potentially shorter time to achieving pregnancy 

This approach supports a more personalised and evidence-based fertility journey.

Is PGT-A necessary for every IVF cycle?

No, PGT-A is not required for every patient. Its use depends on factors such as age, medical history, previous IVF outcomes, and personal preferences.

A fertility specialist will advise whether PGT-A is appropriate based on individual circumstances.

If you are considering PGT-A to reduce the risk of chromosomal abnormalities, such as Down's Syndrome, you may discuss this option with your fertility specialist to receive personalised advice.

Who should consider PGT-A during IVF?

PGT-A is commonly recommended for individuals or couples who: 

  • are of advanced maternal age
  • have experienced recurrent miscarriages
  • have had repeated implantation failure
  • previously had pregnancies affected by chromosomal abnormalities
  • want to prioritise the most viable embryos 

At Sunfert, we aim to ensure that any additional procedures are only advised when there is clear clinical benefit, so patients are not undergoing or paying for steps that are not necessary for their fertility journey and treatment.

Can younger patients benefit from PGT-A?

Yes. While PGT-A is especially beneficial for women of advanced maternal age, younger patients may also benefit by: 

  • improving embryo selection accuracy
  • reducing time to pregnancy
  • minimising the emotional impact of failed cycles 

Clinical evidence suggests it can enhance decision-making across different age groups.

Can PGT-A guarantee a successful pregnancy?

No, PGT-A does not guarantee pregnancy. While it improves the selection of chromosomally normal embryos and increases the implantation rate, other factors such as uterine health, embryo quality, and overall medical conditions also influence the overall IVF success rates.

Does PGT-A improve IVF success rates?

PGT-A can improve IVF success rates by selecting embryos with the highest implantation potential. Benefits may include: 

  • improved implantation rates
  • reduced miscarriage risk
  • fewer transfer cycles needed 

However, outcomes vary depending on individual patient factors.

How long does it take to get PGT-A results?

PGT-A results are typically available within 2 to 3 weeks after the embryo biopsy.
This timeframe allows for detailed genetic analysis and accurate reporting to guide the next step in the IVF treatment plan.

How does PGT-A work using advanced genetic technology?

PGT-A is performed using Next-Generation Sequencing (NGS), a highly precise technology that analyses all 23 chromosome pairs simultaneously.

The process involves: 
1. biopsy of a few cells from the embryo 
2. DNA analysis using NGS 
3. identification of chromosomal abnormalities 


This detailed screening enables accurate embryo selection prior to transfer.

Does PGT-A detect all genetic diseases?

No. PGT-A specifically screens for chromosomal abnormalities (aneuploidies) and does not detect single-gene disorders.

For inherited genetic disorder, required a different test called PGT-M (Pre-implantation Genetic Testing for Monogenic disorders).

Is embryo biopsy safe for the embryo?

Embryo biopsy is considered safe when performed by experienced and well-trained gentic scientists following established laboratory protocols.

The procedure involves removing a small number of cells from the outer layer of the embryo, which does not develop into the fetus.

At Sunfert, strict quality control measures and laboratory protocols are followed by all clinical team members, including embryologists and genetic scientists, to ensure the highest standards of embryo safety.

Ready to start your fertility journey?

Book now

The Biological Clock

This tool indicates:

  • Natural conception per month if you have no fertility issues
  • IVF success rate at the same age
  • When to seek help after months of unsuccessful attempts

If you are concerned at any stage – we recommend booking a doctor appointment or a free nurse consultation. The sooner you make a plan the better your chances in the long term.

When to seek advice early

If you have polycystic ovaries, endometriosis, or have been through a cancer diagnosis; we recommend you get in touch quickly so we can talk you through all your options and give you the greatest possible chance of success.

If you’re a single woman considering motherhood in the future; it’s best to approach us early and consider egg freezing as this can be an option for you while you have a higher ovarian reserve and healthier eggs.

Set your age and the months you’ve been trying to conceive
26
2
Your chance of having a baby per month for fertile couples
Your chance of having a baby per IVF cycle (if experiencing infertility)

Body Mass Index calculator

Being overweight or underweight can reduce fertility, so it is important to keep your body weight within the normal healthy range.

Body Mass Index (BMI) is an indication of your body weight and can be calculated by dividing weight by height. You should aim for a BMI of between 20 and 25, as this will optimise your chances of conception.

Woman’s BMI below 19

Even in these modern times, nature knows best. If a woman's BMI falls below 19, the body senses famine and ovulation is switched off to prevent the risk of having a baby with malnutrition. Excessive exercise can reduce body fat and increase muscle mass to a point where periods cease for the same reason. Risk of miscarriage is also increased in women with a low BMI.

Being underweight

If a woman's BMI falls below 19, the body senses famine and ovulation is switched off to prevent the risk of having a baby with malnutrition. Excessive exercise can reduce body fat and increase muscle mass to a point where periods cease for the same reason. Risk of miscarriage is also increased in women with a low BMI.

BMI’s greater than 30

This can reduce fertility by 50%. Pregnancy for women with a 30+ BMI is often associated with problems such as maternal diabetes, high blood pressure, big babies and increased risk of caesarean section.

Add your height and weight to calculate your BMI